In the original publication, information regarding ''ustekinumab'' was incorrectly published under the Methods section. The correct information in the section ''Antibodies and Control Protein'' should be ''(secukinumab, 150 mg/mL; ixekizumab, 90 mg/mL; adalimumab, 50 mg/mL; ustekinumab 90 mg/ml)''. Infliximab, which is mentioned in that section, was not used in the study.
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